Sagimet Biosciences Inc. (NasdaqGM: SGMT)
Health Care · Biotechnology · US
$10.35
-1.90% today · +39.7% 1Y
Sagimet Biosciences Inc. (NasdaqGM: SGMT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $655.77M and employs 16 people.
Over the last twelve months the share price has gained 39.7%, trading between 4.50 and 10.60.
Tweenvest scores Sagimet Biosciences Inc. across four factors: quality 30/100. Its strongest factor is quality.
SGMT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $655.77M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.25
- Dividend yield
- —
- Beta (5Y)
- 3.40
- 52-week high
- $10.60
- 52-week low
- $4.50
- Avg volume (3M)
- —
- Shares outstanding
- 62.16M
- Employees
- 16
- Next earnings
- —
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- ISIN
- US7867001049
- Founded
- 2006
- Listed since
- Jul 14, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.10 | -1.39% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.85 | -0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.36 | +0.40% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.04 | -0.33% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.94 | -0.91% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.54 | -5.85% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.